A New Review of Real-world Experiences of Fluocinolone Acetonide (0.2 μg/day) Intravitreal Implant in the Treatment of Diabetic Macular Oedema

LONDON, October 15, 2015 /PRNewswire/ --

European Ophthalmic Review, the peer-reviewed journal, has published a review highlighting the benefits of Real-world Experiences of Fluocinolone Acetonide (0.2 μg/day) Intravitreal Implant in the Treatment of Diabetic Macular Oedema.

     (Logo: http://photos.prnewswire.com/prnh/20151014/276718LOGO )

Fluocinolone acetonide intravitreal implant (ILUVIEN®, FAc intravitreal implant) is approved for clinical use in Europe and US for the treatment of diabetic macular oedema (DMO). In Europe, the implant is indicated for chronic DMO patients who are insufficiently responsive to available therapies. The use of FAc intravitreal implants has been shown to be effective in pivotal clinical trial studies.

Case reports and case series of FAc intravitreal implants in chronic DMO are now emerging and combined analysis of these reveals interesting findings that complement the findings in the clinical studies. Visual improvement and central retinal thickness reductions are similar to those of the clinical trials, which is surprising given that treatments often perform less well in the real-world. In addition, the incidence of intraocular pressure (IOP) elevations is lower than reported in the clinical studies. However, further follow-up is ongoing and this needs to be confirmed in a larger population of subjects. This article reviews some of these important real-world data and their likely impact on future chronic DMO treatment practice as well as the impact in terms of the functional benefit to patients with impaired vision.

The full peer-reviewed, open-access article is available here:

http://www.touchophthalmology.com/articles/real-world-experience-fluocinolone-acetonide-02-gday-intravitreal-implant-treatment

Note to the Editor

touchOPHTHALMOLOGY (a division of Touch Medical Media) publishes the European Ophthalmic Review, a peer-reviewed, open access, bi-annual journal specialising in the publication of balanced and comprehensive review articles written by leading authorities to address the most important and salient developments in the field of ophthalmology. The aim of these reviews is to break down the high science from 'data-rich' primary papers and provide practical advice and opinion on how this information can help physicians in the day to day clinical setting. Practice guidelines, symposium write-ups, case reports, and original research articles are also featured to promote discussion and learning amongst physicians, clinicians, researchers and related healthcare professionals.

http://www.touchOPHTHALMOLOGY.com

For inquires please contact: Nicola Cartridge, Managing Editor,[email protected], T: +44(0)207-193-3186, F: +44(0)207-657-3002

Providing practical opinion to support best practice for busy healthcare professionals.

SOURCE touchOPHTHALMOLOGY.com